IA
AIMT

IFP Advisors’s Aimmune Therapeutics AIMT Stock Holding History

IFP Advisors’s Portfolio AIMT Stock Details AIMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-15
Closed -$517 – 3195
2020
Q3 		$1K Sell
15
-2,645
-99% -$56.3K ﹤0.01% 2771
2020
Q2 		$44K Sell
2,660
-466
-15% -$7.91K ﹤0.01% 1281
2020
Q1 		$43K Buy
3,126
+594
+23% +$15.2K ﹤0.01% 1196
2019
Q4 		$82K Buy
2,532
+488
+24% +$13.6K 0.01% 1051
2019
Q3 		$44K Buy
+2,044
New +$41.7K ﹤0.01% 1431
2019
Q1 		– Sell
-111
Closed -$3K – 3754
2018
Q4 		$3K Hold
111
– – ﹤0.01% 3100
2018
Q3 		$3K Sell
111
-1,397
-93% -$39.5K ﹤0.01% 3479
2018
Q2 		$41K Sell
1,508
-287
-16% -$8.78K ﹤0.01% 2044
2018
Q1 		$68K Hold
1,795
– – ﹤0.01% 1624
2017
Q4 		$68K Buy
1,795
+1,778
+10,459% +$57.4K ﹤0.01% 1639
2017
Q3 		$0 Hold
17
– – ﹤0.01% 4292
2017
Q2 		$0 Hold
17
– – ﹤0.01% 4291
2017
Q1 		$0 Hold
17
– – ﹤0.01% 4212
2016
Q4 		$0 Hold
17
– – ﹤0.01% 4208
2016
Q3 		$0 Buy
+17
New +$229 ﹤0.01% 4125

IFP Advisors's AIMT Position: Q4 2020 in Review

IFP Advisors sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 15 shares — an estimated $517 sold.

IFP Advisors first reported a position in AIMT in Q3 2016 and held it in 15 quarters. The position peaked at $82K in Q4 2019. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

  • IFP Advisors reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
  • IFP Advisors sold 15 Aimmune Therapeutics shares in Q4 2020, an estimated $517.
  • IFP Advisors first reported a position in Aimmune Therapeutics in Q3 2016 and held it in 15 quarters.
  • IFP Advisors's Aimmune Therapeutics position peaked at $82K in Q4 2019.
  • 0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on IFP Advisors's 13F filing for Q4 2020, filed 25 Jan 2021.